Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03501979
Recruitment Status : Recruiting
First Posted : April 18, 2018
Last Update Posted : April 11, 2019
Sponsor:
Collaborators:
Translational Breast Cancer Research Consortium
Johns Hopkins University
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Erica Stringer-Reasor, University of Alabama at Birmingham

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : September 2023